Jonathan S. Leventhal

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Dermatologic toxicities associated with radiation therapy in women with breast cancer”.

Dermatologic toxicities associated with radiation therapy in women with breast cancer

International Journal of Women’s Dermatology(2020)10.1016/j.ijwd.2020.07.015

N/A

0DataRank · unranked

72 citations

Michelle Ferreira, Jonathan S. Leventhal, Julie Y. Ramseier

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines

The Oncologist(2020)10.1002/onco.13552

N/A

0DataRank · unranked

67 citations

V. Sibaud, Milan J. Anadkat, Benjamin H. Kaffenberger, Jonathan S. Leventhal, Kathleen Guindon +2 more

Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review)

Oncology Reports(2020)10.3892/or.2020.7911

N/A

0DataRank · unranked

16 citations

Brianna Olamiju, Jonathan S. Leventhal, Emily Coleman

Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series

JAAD Case Reports(2020)10.1016/j.jdcr.2020.05.010

N/A

0DataRank · unranked

13 citations

Jamie K. Hu, William Damsky, Kelly Olino, Harriet M. Kluger, James Clune +5 more

Consensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi survey

British Journal of Dermatology(2022)10.1111/bjd.21852

N/A

0DataRank · unranked

19 citations

Rohan Shah, Christian Menzer, Abdullah Aleisa, Mary Sun, Bernice Y. Kwong +27 more

PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens

Nature(2023)10.1038/s41586-023-06217-y

N/A

0DataRank · unranked

77 citations

Noah I. Hornick, Aarthi Venkat, Ivana William, Kathryn Clulo, Srividhya Venkatesan +13 more

The effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy

Journal of the American Academy of Dermatology(2023)10.1016/j.jaad.2023.01.002

N/A

0DataRank · unranked

4 citations

Ryland D. Mortlock, Jolanta Pach, Jeffrey M. Cohen, Jonathan S. Leventhal, Annika Belzer

Factors associated with the use of adjuvant radiation therapy in stage III melanoma

Frontiers in Oncology(2023)10.3389/fonc.2023.1005930

N/A

0DataRank · unranked

3 citations

Victor Lee, Beverly Yu, Fatima N. Mirza, Cheryl K. Zogg, Daniel Yang +4 more

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-007675

N/A

0DataRank · unranked

27 citations

Yevgeniy R. Semenov, Allireza Alloo, Daniel Q. Bach, Allison Betof Warner, Amina Bougrine +36 more

The treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors with biologic therapy: A single-institution retrospective study at a tertiary care cancer center

Journal of the American Academy of Dermatology(2025)10.1016/j.jaad.2025.04.075

N/A

0DataRank · unranked

2 citations

Kailyn Valido, Matthew D. Vesely, Jonathan S. Leventhal, Ana B.W. Greenberg